Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
23 mai 2023 16h00 HE
|
Phathom Pharmaceuticals
Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year endIf approved, vonoprazan would be the first innovative acid...
Phathom Pharmaceuticals Reports First Quarter 2023 Results
10 mai 2023 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
09 mai 2023 08h00 HE
|
Phathom Pharmaceuticals
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristicsMeta-analysis...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
12 avr. 2023 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
04 avr. 2023 08h00 HE
|
Phathom Pharmaceuticals
Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarterCombined commercial...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
28 févr. 2023 08h00 HE
|
Phathom Pharmaceuticals
Meeting scheduled in March 2023 with the U.S. Food and Drug Administration (FDA) to discuss stability data and resubmission requirements for erosive GERD and H. pylori New Drug Applications FLORHAM...
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
08 janv. 2023 18h00 HE
|
Phathom Pharmaceuticals
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data...
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
03 janv. 2023 16h01 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
08 nov. 2022 17h00 HE
|
Phathom Pharmaceuticals
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to...
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
03 nov. 2022 08h30 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...